New Fibroid Treatment - Oriahnn

On May 29, 2020, the FDA approved ORIAHNN, the first ever nonsurgical treatment specifically indicated for heavy menstrual bleeding due to fibroids in premenopausal women. Uterine fibroids are the most common benign tumors in women of reproductive age, with heavy menstrual bleeding being one of the most important symptoms prompting women to seek treatment. Fibroids are the leading cause of hysterectomy in the US and, although surgical treatments are available, many women may prefer not to have surgery. Now, ORIAHNN may be a medical treatment option for these women.On May 29, 2020, the FDA approved ORIAHNN, the first ever nonsurgical treatment specifically indicated for heavy menstrual bleeding due to fibroids in premenopausal women. Uterine fibroids are the most common benign tumors in women of reproductive age, with heavy menstrual bleeding being one of the most important symptoms prompting women to seek treatment. Fibroids are the leading cause of hysterectomy in the US and, although surgical treatments are available, many women may prefer not to have surgery. Now, ORIAHNN may be a medical treatment option for these women.

 

ORIAHNN is the only FDA-approved oral medication specifically made to help lighten
heavy periods due to uterine fibroids1

ORIAHNN is different. It's not a surgery, procedure, or birth control. It’s an oral medication that’s clinically proven to reduce heavy
menstrual bleeding due to uterine fibroids in as soon as 1 month.

 

ORIAHNN clinical trial results

ORIAHNN was studied in two 6-month clinical trials, including premenopausal women with heavy periods due to uterine fibroids aged 25-53.1

ORIAHNN was proven to lighten heavy periods in about

ORIAHNN™ was proven to lighten heavy periods in about 7 in 10 women

women1*

This meant bleeding volume was reduced by at least 50% from start of trial, and to below 80 mL (about 1/3 of a cup) at the final month of treatment.1

*Compared with about 1 in 10 women taking placebo.

Average bleeding was reduced by about 89% (-188 mL)8†

Measuring cup depicting that the average menstrual bleeding while taking ORIAHNN™ was reduced by about 89%

Compared with an increase of about 9% (+12 mL) in women taking placebo. Results shown are from start of trial to Month 6. These results are from Trial 2. Trial 1 results were similar.

Average periods were reduced quickly—by half at Month 1 and about 85% at Month 38‡

Measuring cup depicting the amount of menstrual bleeding at the start of the ORIAHNN™ clinical trial

Start of Trial

ORIAHNN PLACEBO
228 mL 256 mL

Measuring cup depicting menstrual bleeding after month 1 of the ORIAHNN™ clinical trial

Month 1

ORIAHNN PLACEBO
-122 mL -16 mL

 

Measuring cup depicting menstrual bleeding after month 3 of the ORIAHNN™ clinical trial

Month 3

ORIAHNN PLACEBO
-194 mL -27 mL

Measuring cup depicting menstrual bleeding after month 6 of the ORIAHNN™ clinical trial

Month 6

ORIAHNN PLACEBO
-188 mL +1